A 19-year-old in Berlin with beta-thalassaemia no longer needs blood transfusions after getting Casgevy, the first CRISPR gene-editing drug used in Germany.
Laverock Therapeutics is shifting from ex vivo cell therapies to launch in vivo CAR-T and genetic medicine programs. The company aims to tackle solid tumors and tough genetic disorders using programmable gene control.
Novo Nordisk has signed a licensing deal worth up to $2.6 billion for Hengrui Pharma’s once-weekly oral GLP-1 GIP agonist HRS-1596. The move shakes up the metabolic disease market.
Anthropic's bold assertion that its AI discovered a new gene editing mechanism has ignited controversy, exposing the risks of overhyping artificial intelligence in biotech.
GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.
